LifeStance upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs upgraded LifeStance to Buy from Neutral with a $10 price target Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. The analyst believes LifeStance’s continued operational execution will continue in 2025, and on an organic basis, Goldman’s analysis suggests its EBITDA can grow 27% through 2027.